Spectral Pattern of Pancreatic Cancer and Metabolomic Biomarker

In order to find a curable stage of pancreatic cancer (PC) a discovery of a biomarker is essential.A new approach based on spectroscopic methods that focus on the specific molecular signature of blood plasma components has been introduced lately.Results of pilot study showed a high potential of the combination of chiroptical and vibrational spectroscopy as a promising tool in the identification of patients with PC (1).Moreover collected plasma samples were thereafter examined by Metabolomic analysis.The aim was to determine new potencial biomarker of pancreatic cancer.Plasma samples collected from 23 patients with pancreatic cancer and 24 controls were analysed by chiroptical spectroscopy, specifically electronic circular dichroism (ECD) and Raman optical activity (ROA), which are inherently sensitive to the 3D structure of chiral molecules.(2,3) To obtain more structural information, the ROA and ECD measurements were supplemented by conventional infrared (IR) and Raman spectroscopies.After this "first sieve" a Metabolomic study was performed.The spectra obtained from all four spectral methods were processed by linear discriminant analysis (LDA) showing a clear separation of DMPCs and DM2 patients.The quality of the established statistical model was confirmed by leave-one-out cross-validation where sensitivity and specificity reached 90%.Using metabolomic profiling we discovered potencial molecules shoving high intensity in cancer group and low intensity in control group.These molecules discovered by metabolomic analysis are: Chenodeoxycholic acid, Hexadec-2-enoyl karnitin, Linolic acid and Dekanoyl karnitin.The results obtained in this pilot study show a high potential of the combination of spectroscopy and metabolomic study in the identification of potential biomarker of PC.Supported by Ministry of Health of the Czech Republic, grant nr.16-31028A.All rights reserved.